NMS · Financial Statements
Tarsus Pharmaceuticals, Inc. (TARS) Financial Statements
$72.22
NMS: TARS
Market Cap $3.11B
Overview Financials Dividend Tarsus Pharmaceuticals, Inc. most recently reported annual revenue of $451.0M, net profit of $-66.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $57.0M $26.0M $17.0M $183.0M $451.0M Operating Profit $-12.0M $-63.0M $-143.0M $-121.0M $-71.0M Net Profit $-14.0M $-62.0M $-136.0M $-116.0M $-66.0M EPS $-0.67 $-2.52 $-4.62 $-3.07 $-1.59 Op Margin -21.3% -242.9% -820.5% -65.9% -15.7%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $179.0M $228.0M $265.0M $377.0M $562.0M Total Liabilities $12.0M $35.0M $69.0M $152.0M $219.0M Cash $171.0M $72.0M $225.0M $95.0M $184.0M Borrowings $2.0M $20.0M $30.0M $72.0M $94.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $4.0M $-49.0M $-117.0M $-83.0M $-12.0M Investing Cash Flow $-1.0M $-145.0M $135.0M $-201.0M $-52.0M Financing Cash Flow $0 $0 $0 $0 $0 Net Cash Flow $3.0M $-100.0M $153.0M $-128.0M $89.0M Free Cash Flow $3.0M $-50.0M $-123.0M $-85.0M $-22.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.84 EV / EBITDA -90.79 FCF Yield 1.86% Quick Ratio 3.17 Interest Coverage -5.63 Return 1Y 35.99% Return 3Y 133.87% Return 5Y 122.23%
Screens featuring this stock